March 20, 2026

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: 48.3% Upside Potential and Strong Buy Ratings Signal Attention

Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a notable player in the healthcare sector, is capturing investor attention with a substantial 48.3% potential upside, underpinned by strong buy..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unveiling a 101% Potential Upside in the Biotech Sector

Nurix Therapeutics, Inc. (NASDAQ: NRIX), a pioneering entity in the biotechnology sector, is capturing investor attention with a staggering potential upside of 101.07%. Specializing in the..

uniQure N.V. (QURE) Stock Analysis: Exploring a Potential 151% Upside in Biotechnology

For investors with an eye on the biotechnology sector, uniQure N.V. (NASDAQ: QURE) presents a compelling opportunity, marked by its innovative approach in treating rare and..

AMN Healthcare Services Inc (AMN): Investor Outlook on a Promising 21.32% Upside

AMN Healthcare Services Inc (AMN), a pivotal player in the U.S. healthcare sector, offers a broad range of technology-enabled workforce solutions and staffing services. Serving various..

Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring a 116.82% Potential Upside in the Medical Device Sector

Beta Bionics, Inc. (NASDAQ: BBNX), a pioneering force in the medical devices industry, is making waves with its innovative solutions to enhance the health and quality..

Replimune Group, Inc. (REPL) Stock Analysis: Evaluating an 86% Potential Upside with Robust Analyst Ratings

Replimune Group, Inc. (NASDAQ: REPL), a promising player in the biotechnology sector, is capturing attention with its innovative approach to cancer treatment through oncolytic immunotherapies. Headquartered..

ArriVent BioPharma, Inc. (AVBP)

⚠️ No article content returned.

..

SI-BONE, Inc. (SIBN) Stock Analysis: Navigating a 100.99% Potential Upside in the Healthcare Sector

Investors seeking exposure in the healthcare sector, particularly in medical devices, may find SI-BONE, Inc. (NASDAQ: SIBN) an intriguing prospect. With its innovative approach to orthopedic..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Exploring a 55.79% Potential Upside in Biotech Innovations

Bicara Therapeutics Inc. (NASDAQ: BCAX) is making waves in the biotechnology sector, offering investors a compelling opportunity with its groundbreaking approach to cancer treatment. With a..

GH Research PLC (GHRS): Investor Outlook and 165% Potential Upside Amidst a Robust Pipeline

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company based in Dublin, Ireland, is capturing investor attention with its promising pipeline in the burgeoning field of..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Biotech with 43.67% Potential Upside in the Healthcare Sector

Spyre Therapeutics, Inc. (SYRE), a dynamic player in the biotechnology sector, is capturing the attention of the investment community with its promising developments in the treatment..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotechnology Powerhouse with Over 107% Upside Potential

Praxis Precision Medicines, Inc (NASDAQ: PRAX) is making waves in the biotechnology sector with its innovative approach to treating central nervous system (CNS) disorders. As a..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: Navigating a 50% Upside Potential with Promising Cancer Therapies

Arcus Biosciences, Inc. (NASDAQ: RCUS) is carving a niche in the biotechnology sector with its pioneering approach to cancer therapies. As a clinical-stage biopharmaceutical company, Arcus..

Geron Corporation (GERN) Stock Analysis: A 119% Potential Upside in Biotech Investment

Geron Corporation (NASDAQ: GERN), a biopharmaceutical company with a focus on oncology therapeutics, presents a compelling case for investors keen on biotechnology prospects. With a market..

Pharvaris N.V. (PHVS) Investor Outlook: 76% Potential Upside in Biotech Innovation

Pharvaris N.V. (PHVS), a Swiss-based biotechnology company, is making waves in the healthcare sector with its pioneering approach to treating rare diseases. With a market capitalization..

CareDx, Inc. (CDNA) Stock Analysis: 40.99% Potential Upside Sparks Investor Interest

CareDx, Inc. (NASDAQ: CDNA), a key player in the healthcare sector’s diagnostics and research industry, is capturing investor attention with a notable potential upside of 40.99%...

Criterium Energy builds optionality across Indonesian gas and oil portfolio

A portfolio combining producing oil fields and near-term gas developments in Indonesia aims to support more stable and scalable cash flow...

Tirupati Graphite strengthens operational footing

Tirupati Graphite shows improving operational stability and moves closer to resuming share trading as its recovery gains traction...

Real Estate Credit Investments: 10% Yield Strategy Backed by Senior Secured Property Lending (Video)

A 10%+ yield backed by senior secured loans sits at the heart of Real Estate Credit Investments’ strategy. With a strong recovery track record and consistent..

Gamma Communications appoints Damien Maltarp as CFO and Executive Director

Gamma Communications plc has appointed Damien Maltarp as Chief Financial Officer and Executive Director, succeeding Bill Castell. Maltarp brings over 15 years of telecoms and financial..
Search

Funds

March 20, 2026

Criterium Energy builds optionality across Indonesian gas and oil portfolio

A portfolio combining producing oil fields and near-term gas developments in Indonesia aims to support more stable and scalable cash flow...

Tirupati Graphite strengthens operational footing

Tirupati Graphite shows improving operational stability and moves closer to resuming share trading as its recovery gains traction...

Real Estate Credit Investments: 10% Yield Strategy Backed by Senior Secured Property Lending (Video)

A 10%+ yield backed by senior secured loans sits at the heart of Real Estate Credit Investments’ strategy. With a strong recovery track record and consistent dividend policy, the company is positioning itself to balance opportunity with risk in a shifting market...

Gamma Communications appoints Damien Maltarp as CFO and Executive Director

Gamma Communications plc has appointed Damien Maltarp as Chief Financial Officer and Executive Director, succeeding Bill Castell. Maltarp brings over 15 years of telecoms and financial leadership experience and will join by September 2026...
Search

Funds

March 20, 2026

FTSE 100

Funds